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Abstract
Background: Nonresected, nonmetastatic (NR- M0) pancreatic cancer involves both 
locally advanced pancreatic cancer and patients who did not undergo resection due 
to poor health status or patient preference. This study investigates nationwide trends 
of characteristics, treatment, and survival of patients with NR- M0 pancreatic 
cancer.
Methods: From the Netherlands Cancer Registry, all patients diagnosed with pan-
creatic cancer between 2006 and 2014 were selected. Chemotherapy and overall sur-
vival (OS) of NR- M0 patients were evaluated for 3- year time periods and 2 age 
groups using chi- square tests for trend and Cox proportional hazard regression 
analysis.
Results: Of 18 234 patients, 33% had NR- M0 pancreatic cancer, which decreased 
over time (in consecutive 3- year periods: 38%- 33%- 28%, P < 0.001). Of 5964 NR- 
M0 patients, 52% was over 75 years of age, 16% received chemotherapy, and median 
OS was 5.1 months. Chemotherapy use increased over time in younger patients 
(<75 years: from 23 to 36%, P- trend < 0.001, ≥75 years: 3% to 4%, P- trend = 0.053). 
In multivariable survival analysis, elderly age, low SES, nonconfirmed cancer, stage 
II- III disease, and earlier years of diagnosis were independently associated with a 
worse OS. Age of patients who received chemotherapy increased over time (median 
62- 66 years) and median OS was 10.4 months without significant differences be-
tween time periods (P = 0.177) or age groups (P = 0.207).
Conclusions: Overall survival of NR- M0 pancreatic cancer remains poor which is 
partly related to advanced age of many patients. Despite an increase, chemotherapy 
is infrequently used. Future research should investigate to what extent the more 
widespread use of chemotherapy could improve survival in relation to age- related 
morbidity.
K E Y W O R D S
chemotherapy, nonresected, pancreatic adenocarcinoma, survival
2 |   van der GeeST eT al.
1 |  INTRODUCTION
Pancreatic cancer remains one of the most lethal cancers with 
a 5- year survival rate of 5- 7%.1,2 Since symptoms usually 
emerge late, about 50%- 60% of patients are diagnosed with 
metastatic disease.3,4 Only 10%- 20% of patients have resect-
able disease. The intermediate group of 30%- 40% generally is 
referred to as locally advanced pancreatic cancer (LAPC).5,6 
Nonresected patients in cancer registries have metastatic or 
unresectable disease diagnosed at imaging or at time of sur-
gical exploration or are ineligible for surgery due to a poor 
health status or patient preference. As a result of increased 
resection rates for pancreatic cancer,7,8 characteristics of the 
patient group with nonresected, nonmetastatic (NR- M0) dis-
ease may have changed.
For patients with pancreatic cancer not undergoing resec-
tion, chemotherapy is the main treatment modality. In patients 
with metastatic disease, population- based studies have shown 
that the administration of palliative chemotherapy steeply 
increased in the past decades.3,9,10 Notably, this increased 
use of chemotherapy was found in the gemcitabine era, and 
thus, before the studies on FOLFIRINOX (5- fluorouracil, 
leucovorin, irinotecan, and oxaliplatin) and nab- paclitaxel 
plus gemcitabine reported favorable results compared with 
gemcitabine alone.11,12 No randomized controlled trials have 
yet been published on these chemotherapy schemes in pa-
tients with LAPC. Despite a lack of randomized studies, an 
increased use of chemotherapy may also be found in patients 
with NR- M0 disease.
Population- based data on treatment and survival of pa-
tients with LAPC or NR- M0 disease are scarce.13 In addition, 
little is known about survival of elderly patients with NR- M0 
disease, with or without chemotherapy.
Therefore, the aim of this nationwide study was to investi-
gate time trends in characteristics, treatment, and survival of 
patients with NR- M0 pancreatic cancer.
2 |  METHODS
2.1 | Data collection
The Netherlands Cancer Registry (NCR) records data on all 
patients with newly diagnosed cancer in the Netherlands, a 
country with 17 million inhabitants. Since 1989, newly diag-
nosed malignancies are notified to the NCR by the automated 
pathological archive (PALGA), supplemented with data 
from the National Registry of Hospital Discharge Diagnoses. 
Completeness is estimated to be at least 95%. Trained reg-
istrars in all Dutch hospitals routinely extract data on pa-
tient, tumor, and treatment characteristics. Tumor location 
and histology are registered according to the International 
Classification of Diseases for Oncology (ICD- O- 3).14 The 
tumour- node- metastasis (TNM) staging classification is used 
(6th edition in 2003- 2009,15 7th edition in 2010- 201616) for 
pathologically confirmed malignancies, while in other cases, 
a 1- digit extend of disease (EoD) is recorded. From 2012 on-
wards, TNM was recorded for all patients. Actual vital sta-
tus (dead or alive, date of death or emigration) is obtained 
by periodically linking the NCR to the Municipal Personal 
Records Database which keeps record on the vital status of 
all Dutch inhabitants.
2.2 | Patients
From the NCR, all patients were selected who were diagnosed 
with pancreatic (ductal) adenocarcinoma between 2006 and 
2014 (ICD- O- 3 C25, morphology codes 8010, 8012, 8020, 
8140,8141, 8260, 8310, 8440, 8480, 8481, 8490, 8500, 8560, 
or a nonconfirmed supposed adenocarcinoma). Patients diag-
nosed at autopsy, younger than 18 years or residing abroad, 
were excluded. The total population was divided into three 
groups: resected, nonresected nonmetastatic (NR- M0), and 
metastatic pancreatic cancers. Since this division was based 
on findings of imaging and surgical exploration, a number 
of patients with nonresected disease underwent a laparotomy 
or laparoscopy (11% of NR- M0 patients in 2012- 2014). The 
intermediate group of NR- M0 patients was the focus of the 
present study.
The study period was evenly divided into three 3- year pe-
riods: 2006- 2008, 2009- 2011, and 2012- 2014. Patients were 
divided into two age groups: younger patients <75 years and 
elderly patients ≥75 years at diagnosis. Comorbidity was re-
corded regionwide in 2 out of 9 Dutch cancer regions (16% 
of all patients) according to a slightly modified version of 
the Charlson classification. Serious comorbid conditions 
included chronic obstructive pulmonary diseases, cardio-
vascular diseases, cerebrovascular diseases, digestive tract 
diseases, diabetes mellitus, and other serious diseases. The 
number of comorbidities was categorized into three groups 
(0, 1, and ≥2). In addition, due to the nature of the NCR, 
information on previous malignancies was available in all pa-
tients. Furthermore, socioeconomic status (SES)17 was based 
on reference data from The Netherlands Institute for Social 
Research. Social deprivation scores were derived from data 
on income, education, and occupation per 4- digit postal code 
and were broken into three SES categories (high: 1st- 3rd, in-
termediate: 4th- 7th, and low: 8th- 10th deciles). Both types 
of information on tumor stage (TNM and EoD) were com-
bined into one summary stage: (a) “localized”: tumor con-
fined to the pancreas (TNM I); (b) “nonlocalized”: “tumor 
extension into adjacent organs or tissues and/or into regional 
lymph nodes” (TNM II- III); (c) “metastatic”: distant metas-
tasis (TNM IV); and (d) unknown stage. In the period 2012- 
2014, a distinction between stage II (T3/N1M0) and stage 
III (T4M0) could be made. Registered treatments comprise 
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tumor resection, chemotherapy, and/or local treatment such 
as radiotherapy applied for stage at diagnosis. No information 
was available about type of chemotherapy treatment. Survival 
time was calculated from the date of diagnosis to the date of 
death or emigration. Patients who were alive on 1 February 
2017 were censored (1.6%). To investigate early mortality 
after diagnosis, 30- and 90- day mortality of any cause after 
date of diagnosis were calculated.
2.3 | Statistical analysis
Chi- square tests for trend were used to analyze characteristics 
and treatment of the NR- M0 patients in consecutive 3- year 
periods. A two- sided P- value <0.05 was considered statisti-
cally significant. To evaluate overall survival of NR- M0 pa-
tients, Kaplan- Meier analyses and log- rank tests were used, as 
well as univariable and multivariable Cox proportional hazard 
analyses. In multivariable models, a backward stepwise se-
lection was used with a P > 0.10 for removal of variables in 
likelihood ratio tests. Characteristics that were included (if ap-
plicable) were time periods, age, sex, history of cancer, SES, 
pathological confirmation of cancer, tumor location, summary 
tumor stage, chemotherapy, and local treatment. Sensitivity 
analyses were performed using regionwide data to investigate 
associations of the number and type of comorbid conditions 
(adjusted for predictors derived from the multivariable model 
in all patients). STATA/SE (version 14.0; STATA Corp., 
College Station, TX, USA) was used in all analyses.
3 |  RESULTS
3.1 | All patients
Median age of 18 234 patients diagnosed with pancreatic 
cancer in 2006- 2014 was 71 years and 37% was 75 years or 
older. Pathology confirmation of pancreatic cancer occurred 
less frequently in patients with nonmetastatic disease (62% 
vs 69% in metastatic disease, P < 0.001). Metastatic disease 
was present in 9934 (54%) of patients, and 2336 (13%) of pa-
tients underwent tumor resection. The remaining 5964 (33%) 
patients had nonresected, nonmetastatic (NR- M0) pancreatic 
cancer. Compared with patients with resected and metastatic 
cancer, patients with NR- M0 pancreatic cancer were older 
(median 75 years vs 67 and 69 years, respectively) and had 
an intermediate overall survival (median 5.1 months [95% 
confidence interval: 4.9- 5.2 months] vs 17.5 and 2.3 months, 
respectively).
Both tumor resection and diagnosis of metastatic dis-
ease increased over time. As a result, NR- M0 pancreatic 
cancer decreased from 2052 (38%) patients in 2006- 2008 
to 2026 (33%) in 2009- 2011 and 1886 (28%) in 2012- 
2014 (P- trend < 0.001). This time trend was found within 
younger and elderly age groups alike, as was shown in 
Figure 1.
3.2 | Patients with NR- M0 pancreatic cancer
Overall, 52% of 5964 patients with NR- M0 pancreatic can-
cer was aged 75 years and older, with a significant increase 
over time (50%, 52%, and 54%, P- trend = 0.008; Table 1). 
Pathological confirmation of cancer occurred in 47% of NR- 
M0 patients and increased over time in younger patients only. 
Arterial involvement was found in 39% of NR- M0 patients 
(TNM stage III, 2012- 2014).
Only 16% (967/5964) of patients with NR- M0 disease 
received chemotherapy, with an increase in consecutive 3- 
year periods from 13%, 17%, to 19% (P- trend < 0.001), 
particularly in younger patients (<75 years: from 23% to 
36%, P- trend < 0.001, Table 1). Of patients over 75 years, 
only 3.5% were treated with chemotherapy (2.8% to 4.3%, 
F I G U R E  1  Distribution of resected, 
nonresected nonmetastatic (NR- M0), and 
metastatic (M1) pancreatic cancer, by 
periods within younger and elderly age 
categories (both P < 0.001)
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P- trend = 0.053). In addition, 5.4% of patients received local 
therapy such as radiotherapy or (sporadic) ablative treatments 
(in consecutive periods: 5.5%- 4.2%- 6.7%, respectively, 
P- trend = 0.121).
At time of 90- days after diagnosis, 33% (1978/5964) of 
patients had died, particularly elderly patients (<75 years: 
24%, ≥75 years: 41%, P < 0.001). No time trends were found 
in early mortality (Table 1). One- and 2- year overall survival 
T A B L E  2  Univariable and multivariable Cox proportional hazards analyses predicting overall survival of patients with nonresected, 
nonmetastatic (NR- M0) pancreatic cancer
N
MS (mo) Univariable analysis Multivariable analysis
Multivariable analysis 
including treatment
HR (95% CI) P- value HR (95%CI) P- value HR (95%CI) P- value
Overall 5964 5.1
Period of diagnosis
2005- 2008 2052 4.9 Ref 0.090 Ref Ref
2009- 2011 2026 5.1 0.93 (088- 0.99) 0.93 (0.87- 0.99) 0.020 0.94 (0.88- 1.00) 0.043
2012- 2014 1886 5.1 0.97 (0.89- 1.02) 0.94 (0.88- 1.00) 0.067 0.99 (0.93- 1.05) 0.664
Age (y)
<75 2870 6.3 Ref <0.001 Ref Ref
≥75 3092 3.9 1.36 (1.29- 1.43) 1.39 (1.31- 1.47) <0.001 1.21 (1.14- 1.28) <0.001
Sex
Male 2745 5.1 Ref 0.249
Female 3219 5.1 1.03 (0.98- 1.08)
History of cancer
No 4956 5.1 Ref 0.008
Yes 1008 4.5 1.10 (1.03- 1.18)
Socioeconomic status
High 1718 5.4 Ref 0.001 Ref Ref
Intermediate 2405 4.9 1.03 (0.96- 1.09) 1.03 (0.96- 1.09) 0.416 1.01 (0.95- 1.08) 0.762
Low 1841 4.7 1.12 (1.05- 1.20) 1.12 (1.05- 1.20) 0.001 1.11 (1.04- 1.19) 0.002
Pathological confirmation
Confirmed 2790 6.0 Ref <0.001 Ref Ref
Not confirmed 3174 4.1 1.18 (1.12- 1.24) 1.09 (1.03- 1.16) 0.004 0.99 (0.94- 1.05) 0.827
Primary tumor location
Head of 
pancreas
4499 5.1 Ref 0.108
Body or tail 784 5.2 0.93 (0.86- 1.00)
Overlapping/
NOS
681 4.7 1.02 (0.94- 1.10)
Summary stage
Localized 1467 4.9 Ref <0.001 Ref Ref
Nonlocalized 3789 5.5 1.04 (0.98- 1.11) 1.27 (1.18- 1.36) <0.001 1.34 (1.25- 1.44) <0.001
Unknown 708 3.5 1.25 (1.14.1.37) 1.31 (1.19- 1.43) <0.001 1.27 (1.16- 1.39) <0.001
Chemotherapy
No 4997 4.2 Ref <0.001 X Ref
Yes 967 10.4 0.53 (0.49- 0.56) 0.56 (0.52- 0.61) <0.001
Local therapy
No 5640 4.7 Ref <0.001 X Ref
Yes 324 11.3 0.55 (0.49- 0.62) 0.77 (0.68- 0.87) <0.001
MS, median survival.
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(OS) of patients with NR- M0 pancreatic cancer were 18% 
and 5%, respectively (data not shown). In consecutive 3- 
year periods, median OS was 4.9, 5.1, and 5.1 months, re-
spectively (P = 0.088, Table 1). For patients aged <75 years 
and ≥75 years, median OS was 6.3 and 3.9 months, respec-
tively (P < 0.001). In the younger age group, a very small 
improvement of OS was found in the study period (from 
5.9 to 6.4 months, P = 0.052; ≥75 years: 3.8 to 4.0 months, 
P = 0.322). Furthermore, median OS was 10.4 months in 
patients who received chemotherapy vs 4.2 months in un-
treated patients (P < 0.001). In the multivariable Cox pro-
portional hazard model, elderly age, low SES, nonconfirmed 
cancer, nonlocalized disease, and diagnosis in earlier years 
of the study period were independently associated with a 
worse OS (Table 2). In a second model including treatment, 
the increased use of chemotherapy could not completely re-
move differences between time periods. Among cases with 
available comorbidity data, only the presence of pulmonary 
disease was additionally associated with a worse OS (n = 864, 
HR = 1.29, 95% CI 1.06- 1.59).
3.3 | Patients with NR- M0 disease who 
received chemotherapy
Median age of 967 patients with NR- M0 pancreatic cancer 
who received chemotherapy was 64 years (range 34- 85 years) 
and increased in consecutive 3- year periods (median age 62, 
63, 66 years, respectively, P = 0.007). Of these treated pa-
tients, as many as 17% did not undergo pathological confir-
mation of cancer (Table 3), which decreased over time (19%, 
20%, 12% of treated patients in consecutive time periods, 
P = 0.015). Most patients receiving chemotherapy had lo-
cally advanced disease (stage II- III: 87%, 91%, and 94% in 
consecutive 3- year periods, P = 0.013; stage III: 67% of 357 
treated patients diagnosed in 2012- 2014). One- and 2- year 
survival were 41% and 11%, respectively. Median OS of 
All 
patients 2006- 2008 2009- 2011 2012- 2014 Chi- square
N = 967% N = 269% N = 341% N = 357% P- trend
Median age 
(range)
64 (34- 85) 62 (34- 83) 64 (36- 84) 66 (38- 85) 0.007
Pathological confirmation
Confirmed 807 (83) 81 80 88 0.015
Not confirmed 160 (17) 19 20 12
Primary tumor
Head of 
pancreas
645 (67) 68 68 64 0.102
Body or tail 206 (21) 22 17 24
Overlapping/
NOS
116 (12) 9.7 14 11
Summary stage
Localized 62 (6.4) 9.7 5.3 5.0 0.013
Nonlocalized 878 (91) 87 91 94
Unknown 27 (2.8) 3.7 3.8 1.1
TNM stage 
I- II- X
117 (33) 33
TNM stage III 240 (67) 67
Local therapy 
(%yes)a
247 (26) 36 19 24 <0.001
Deceased within 
90 days of start 
chemotherapy 
(%yes)
101 (14) 11 16 13 0.342
Median OS 
(95%CI) in mo
10.4 
(9.9- 10.9)
10.5 
(9.4- 11.8)
9.6 
(8.7- 10.7)
10.8 
(10.2- 11.5)
0.177b
CI, confidence interval; NOS, not otherwise specified; OS, overall survival.
aFor example, conventional radiotherapy, SBRT, RFA, and IRE. 
bLog- rank test. 
T A B L E  3  Characteristics of patients 
with nonresected, nonmetastatic (NR- M0) 
pancreatic carcinoma receiving 
chemo(radio)therapy, by time periods
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treated patients was 10.5, 9.6, and 10.8 months in consecutive 
time periods (P = 0.177; Table 3) and did not differ signifi-
cantly between age groups (<75 years: 10.6 and ≥75 years: 
9.2 months, P = 0.207; data not shown).
4 |  DISCUSSION
One- third of patients with pancreatic cancer in the Netherlands 
(2006- 2014) had nonresected, nonmetastatic (NR- M0) dis-
ease. At least half of these nearly 6.000 NR- M0 patients were 
over 75 years of age and two- fifth of patients had stage III 
disease. The median overall survival of NR- M0 pancreatic 
cancer was 5.1 months. Only 16% of NR- M0 patients re-
ceived chemotherapy with a median survival of 10.4 months. 
In the course of our study, a 50% increase in chemotherapy 
use was found within the younger age group (<75 years), 
though without significant improvement of survival.
In the past decade, the resection rate for pancreatic can-
cer in the Netherlands has increased,7,8 whereas detection 
of metastatic disease also increased (stage migration).3 
Consequently, the proportion of patients in the remaining 
group with NR- M0 pancreatic cancer decreased until less 
than one- third in 2012- 2014, while age of patients with NR- 
M0 disease increased. In addition, only 40% of the NR- M0 
patient group in 2014- 2016 had stage III disease. Particularly 
in the remaining 60% of NR- M0 pancreatic cancer patient 
stage I- II, elderly patients were overrepresented (≥75 years: 
68%). Several retrospective studies suggested underutilization 
of surgical treatment in elderly patients with localized pan-
creatic cancer.18-20 However, many NR- M0 patients die soon 
after diagnosis; in our study, 41% of patients over 75 years 
died within 90 days. Though in a previous study comorbidity 
of (elderly) patients was not associated with the application 
of pancreatic surgery,18 a poor general health status at time of 
diagnosis may have precluded surgical treatment. Accurate 
identification of a poor health status of patients is of utmost 
importance for optimal treatment decision making.21
Most patients not eligible for pancreatic surgery due to a 
poor performance status are also not candidates for chemo-
therapy. In the current study period in the Netherlands, the 
administration of chemotherapy to NR- M0 patients was very 
limited (16%), which can largely be attributed to the high 
number of elderly patients with early- stage disease (77% of 
stage I- II and 43% of stage III patients were aged ≥75 years). 
In addition, a restraint of medical oncologists to give chemo-
therapy to elderly patients and patient preferences could have 
added to limited chemotherapy use. Also in the subgroup of 
patients with stage III disease, chemotherapy use in our study 
(34% in 2012- 2014) was limited compared with population- 
based studies in the United States (>50%).13,22 Similar data 
on chemotherapy use were found in a previous study of our 
group in patients with metastatic pancreatic cancer.10
Despite a major increase in chemotherapy use in NR- M0 
patients under 75 years in the current study, overall survival 
hardly improved. However, the study period mainly covers 
the gemcitabine era, chemotherapy use and response rates 
may simply be too low to show a survival improvement in 
all NR- M0 pancreatic cancer patients. Possibly, increasing 
prescription of more effective chemotherapy schemes such 
as FOLFIRINOX and nab- paclitaxel with gemcitabine may 
affect overall survival in years following the current study pe-
riod. In addition, the age of chemotherapy- treated patients in 
our study has substantially risen from median 62 to 66 years, 
though still few elderly patients received chemotherapy 
(≥75 years: 11%). A careful selection and better support of 
elderly patients for chemotherapy treatment is therefore rele-
vant and can be facilitated by the use of geriatric assessment 
tools.23
Strikingly, pathological confirmation of cancer in our 
study was lacking in one in six NR- M0 patients who received 
chemotherapy. Because a misdiagnosis cannot be ruled out,24 
pathological confirmation before chemotherapy is highly 
recommended.25 The absence of pathological confirmation 
in treated patients is worrisome and requires further attention 
in multidisciplinary team discussions in the Netherlands.
In recent systematic reviews of nonrandomized stud-
ies with LAPC patients only, approximately one quar-
ter of patients could undergo resection after neoadjuvant 
chemo(radio)therapy26,27 and overall survival of patients 
receiving FOLFIRINOX28 with or without resection was 
24 months,26 which was comparable with survival of pa-
tients with initially resectable pancreatic cancer. In the 
current nationwide study, chemotherapy was combined 
with radiotherapy in only a minority of chemotherapy- 
treated NR- M0 patients.25,29 Re- evaluation of NR- M0 pa-
tients after several months of chemo(radio)therapy may be 
worthwhile to identify patients for possible resection or eli-
gibility for other treatments directed at local tumor control. 
An experienced multidisciplinary team or expert panel can 
provide in this need.
This study has several limitations that are related to the 
retrospective data that were used. Firstly, due to the available 
notification sources, the NCR is at risk of incompleteness of 
pancreatic cancer in elderly patients.30 Therefore, chemother-
apy use and survival of elderly NR- M0 patients may be slightly 
overestimated in our study, while early mortality may be under-
estimated. Survival may also be slightly overestimated because 
some patients of the large group without histological confir-
mation of pancreatic cancer were incorrectly diagnosed.24 
Despite these limitations, the available unselected data of an 
often neglected group of pancreatic cancer patients revealed 
important findings about trends in everyday clinical practice. 
Secondly, survival trends of NR- M0 patients in the course of 
the study period must be interpreted with caution as a result of 
changing characteristics of this subgroup and possible residual 
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confounding of unmeasured characteristics. Thirdly, although 
the proportion of patients with stage III disease in our study 
(12% of all stage I- IV in 2012- 2014) was comparable with other 
population- based studies (7%- 13%),13,19,31 staging may be sub-
optimal in patients who were staged based on imaging only. 
Locally advanced and metastatic disease was found in a sub-
stantial proportion of patients who preoperatively were thought 
to have resectable disease.32,33 Furthermore, TNM staging 
information cannot discriminate between the currently used 
categories of resectable, borderline resectable, and irresectable 
pancreatic cancer, based on the extent of arterial and venous in-
volvement.34 Finally, data on comorbid conditions were avail-
able in only a subgroup of patients, and no information was 
available about performance status and quality of life of pa-
tients. In the future, the Dutch nationwide PAncreatic CAncer 
Project (PACAP) will provide more detailed information.35
In conclusion, our study showed that the group of NR- 
M0 pancreatic cancer patients is heterogeneous, consisting 
of patients with irresectable tumors due to arterial involve-
ment (stage III) and many patients with advanced age and 
(supposed) stage I- II tumors. Despite an increase in the use 
of chemotherapy in younger patients, overall survival of all 
patients hardly improved over the described time period.
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